Rong Tao
Academic / Other · 6 registered clinical trials — 3 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission Diffuse Large B-Cell Lymphoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma Extranodal NK/T-cell Lymphoma, NK/T-cell Lymphoma, Relapsed or Refractory NK/T-Cell Lymphoma | Phase 1 / Phase 2 | 2026-03-23 |
| Recruiting | CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, B-cell Lymphoma Refractory | Phase 1 | 2024-05-31 |
| Unknown | Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | N/A | 2020-04-25 |
| Unknown | Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | 2019-07-01 |
| Completed | Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients Extranodal NK-T-Cell Lymphoma, Nasal Type | — | 2017-03-08 |